C4 Therapeutics outlines milestones through 2028

C4 Therapeutics (CCCC) outlined milestones through 2028 and highlighted recent achievements. Anticipated Key Strategic Milestones: Cemsidomide – In Q1 2026, initiate the Phase 2 MOMENTUM trial of cemsidomide and dexamethasone and complete enrollment within 12 months. In mid-2026, present further analysis of the data from the ongoing Phase 1 trial of cemsidomide and dexamethasone. In 2H 2027, present initial overall response rate data for the MOMENTUM trial. In mid-2028, present efficacy and safety for the MOMENTUM trial. By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later. Relapsed/Refractory Multiple Myeloma: Second Line or Later – In Q2 2026, initiate the Phase 1b trial of cemsidomide in combination with elranatamab and provide incremental updates throughout dose escalation. In mid-2026, share the plan to initiate an additional Phase 1b trial to evaluate cemsidomide in combination with other anti-myeloma agents. In mid-2027, present Phase 1b data from all cohorts evaluating cemsidomide in combination with elranatamab. By early 2028, initiate the Phase 3 trial evaluating cemsidomide in combination with a BCMA BiTE. Early Portfolio: CFT8919 – In Q1 2026, utilize data from the Phase 1 dose escalation trial to inform ex-China clinical development. Early Portfolio: Internal Discovery Projects Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases – By year-end 2028, deliver up to three investigational new drug applications.